Vistagen back on track with social anxiety trials

Vistagen is preparing for a real-world Phase III trial investigating fasedienol to treat social anxiety disorder.

After positive feedback from the US Food and Drug Administration (FDA), the company plans to initiate the trial in the second half of 2024.